Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

OBJECTIVES: To evaluate the efficacy of guselkumab for the treatment of active PsA utilizing composite indices. METHODS: Data were pooled from the phase 3 DISCOVER-1 (n = 381) and DISCOVER-2 (n = 739) studies. In both studies, patients were randomized 1:1:1 to subcutaneous guselkumab 100 mg every 4 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C, Ritchlin, Christopher T, Gossec, Laure, Helliwell, Philip S, Rahman, Proton, Kollmeier, Alexa P, Xu, Xie L, Shawi, May, Karyekar, Chetan S, Contré, Christine, Noël, Wim, Sheng, Shihong, Wang, Yanli, Xu, Stephen, Mease, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891416/
https://www.ncbi.nlm.nih.gov/pubmed/35766811
http://dx.doi.org/10.1093/rheumatology/keac375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891416/
https://www.ncbi.nlm.nih.gov/pubmed/35766811
http://dx.doi.org/10.1093/rheumatology/keac375

Ejemplares similares